Trial 2N-15-10


A Phase 2, Multicenter Study of Tesevatinib in Subjects with Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment with a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomeningeal Metastases

Type: Treatment
Phase: Phase II
Status: Not Open (Closed)
Treatments: Other
Randomized: No
USC Satellite Location: USC Newport Beach Oncology
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Jorge Nieva, M.D.
Other Trial Staff:  Victoria Amran, D.M., Gina Tse, R.N., Kristy Sartor Massopust, Coordinator, Shamim Jhimlee, Coordinator, Eduardo Mejia, D.M., Laurie De Oliveira, Coordinator, Rabia Rehman, Coordinator

Staff may log in to see study documents.

Click here to see trial eligibility criteria and further details at ClinicalTrials.gov





For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3300.